Atagabalin (PD 0200390) is a novel ligand of the voltage-dependent calcium channel (VDCC) α2δ subunit (1 and 2) for treatment for insomnia..

Ataciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC.

AT791 is a novel orally available, small molecule inhibitor of TLR7 and TLR9 with IC50 of 3.33 uM and 0.04 uM respectively, inhibits DNA-TLR9 interaction in vitro.

AT7867 Hcl is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family.

AT7519 trifluoroacetate is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM; less potent to CDK3 and little active to CDK7.

AT-403 (AT403) is a potent, highly selective, nonpeptide NOP agonist with pEC50 of 9.45.

AT-101 is a BH3 mimetic known to be a potent inhibitor of antiapoptotic Bcl-2 family members.

AT-090 is a novel potent, selective nociceptin/orphanin FQ receptor (NOP receptor) agonist with Ki of 5.61 nM.

ASTX660 mesylate is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM.

ASTX660 hydrochloride is a novel potent IAP antagonist that targets the BIR3 domain of cIAP1/2 and XIAP with IC50 of 12 nM and <40 nM.

Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing.

Astin C is a cyclopeptide isolated from the medicinal plant Aster tataricus, inhibits cGAS-STING signaling and the innate inflammatory responses triggered by cytosolic DNAs, inhibits intracellular DNA-induced Ifnb expression with IC50 of 3.42 and 10.83 uM

Astex ERK inhibitor X is a novel potent ERK1/2 inhibitor that inhibits ERK catalytic activity with IC50 of 3 nM in TRK kinase assays.

Astaxanthin, a red dietary carotenoid isolated from Haematococcus pluvialis, is an inhibitor of PPARγ and a potent antioxidant with antiproliferative, neuroprotective and anti-inflammatory activity. Astaxanthin has potential in the treatment of various di

AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.

Aspartame

Asp-AMS, an analogue of aspartyl-adenylate, is an aspartyl-tRNA synthetase inhibitor and also a strong competitive inhibitor of the mitochondrial enzyme.

Aspacytarabine (Astarabine, BST236) is a cytarabine conjugate that shows anti-​neoplastic agents for inhibiting cancer cell growth. .

ASP9436 (ASP-9436) is a potent, selective brain penetrant and orally active phosphodiesterase 10A (PDE10A) inhibitor with IC50 of 8.0 nM, >420-fold selectivity over other PDE subtypes.

ASP6432 (ASP-6432) is a potent and selective antagonist of LPA1 receptor, does-dependently inhibits LPA-stimulated increase in intracellular calcium ion with IC50 of 11 nM.

ASC-J9, is antitumor agent. ASC-J9 suppresses castration-resistant prostate cancer growth via degradation of full-length and splice variant androgen receptors.

AS-605240 is a potent and selective inhibitor of PI 3-kinase γ (PI3Kγ) (IC50 = 8 nM). AS-605240 displays 30-fold selectivity over PI3Kδ and PI3Kβ and 7.5-fold selectivity over PI3Kα.

AS2677131(AS 2677131, AS-2677131) is a novel potent, oral PIKfyve inhibitor that selectively decreases c-Rel binding to gene promoters of IL-12p40 and IL-1β, regulates cytokine production through PIKfyve-c-Rel pathway ( IL-12p40 IC50=4 nM).

AS2541019 is a novel potent, selective, orally active PI3Kδ inhibitor with IC50 of 20.1 nM, >100-fold selectivity over other PI3K isoforms.

AS2521780 is a potent, selective, orally bioavailable PKCθ inhibitor that inhibits combinant human PKCθ enzyme with IC50 of 0.48 nM, >30-fold higher than other PKC isoforms.

AS-1949490 (AS1949490) is a potent, selective SHIP2 inhibitor with IC50 of 0.34/0.62 uM for mouse/human SHIP2.

AS1928370 (ASP8370) is a potent, selective, orally available TRPV1 antagonist with IC50 of 0.51 uM, shows no inhibitory effects on TRPV4, TRPA11, and TRPM8 at 10 uM.

AS 2553627 (AS2553627) is a novel potent, selective pan-JAK inhibitor with IC50 of 0.46, 0.30, 0.14 and 2.0 nM for JAK1, JAK2, JAK3 and TYK2, respectively.

Arylsulfonamide 64B (HIF inhibitor 64B) is a small molecule HIF pathway inhibitor, blocks hypoxia-induced expression of c-Met and CXCR4 and uveal melanoma (UM) cell migration.

Articaine is a dental local anesthetic which contains an additional ester group that is metabolized by estearases in blood and tissue.